Abstract
Cancer cells create a microenvironment that prevents tumor rejection by the host’s immune system. The activation of pattern recognition receptors (PRRs) can elicit an innate immune response and guide the adaptive immune response to overcome this. dsRNA analogs can trigger TLR3, RIG-I, MDA5, NLRP3 and several other PRRs to induce not only robust immune response against cancer but also programmed cell death. This review focuses on the signal pathways activated by dsRNA and examines examples of their clinical application in cancer treatment.
Keywords: Adjuvant, cancer vaccine, cross-presentation, cytokine, cytotoxic T lymphocyte, dendritic cell, double-stranded RNA, inflammasome, immune response, immunoediting, immunotherapy, melanoma differentiation-associated gene 5, nucleotide-binding domain and leucine-rich repeat containing gene family pyrin domain 3, polyadenylic-polyuridylic acid, polyinosinic-polycytidylic acid, poly (I:C12U), poly (ICLC), retinoic acid-inducible gene-I, T helper cell, toll-like receptor, tumor, tumor associated antigen.
Anti-Cancer Agents in Medicinal Chemistry
Title:Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Volume: 14 Issue: 2
Author(s): Bo Jin, Liu-Fang Cheng, Kai Wu, Xiao-Hong Yu and Anthony E.T. Yeo
Affiliation:
Keywords: Adjuvant, cancer vaccine, cross-presentation, cytokine, cytotoxic T lymphocyte, dendritic cell, double-stranded RNA, inflammasome, immune response, immunoediting, immunotherapy, melanoma differentiation-associated gene 5, nucleotide-binding domain and leucine-rich repeat containing gene family pyrin domain 3, polyadenylic-polyuridylic acid, polyinosinic-polycytidylic acid, poly (I:C12U), poly (ICLC), retinoic acid-inducible gene-I, T helper cell, toll-like receptor, tumor, tumor associated antigen.
Abstract: Cancer cells create a microenvironment that prevents tumor rejection by the host’s immune system. The activation of pattern recognition receptors (PRRs) can elicit an innate immune response and guide the adaptive immune response to overcome this. dsRNA analogs can trigger TLR3, RIG-I, MDA5, NLRP3 and several other PRRs to induce not only robust immune response against cancer but also programmed cell death. This review focuses on the signal pathways activated by dsRNA and examines examples of their clinical application in cancer treatment.
Export Options
About this article
Cite this article as:
Jin Bo, Cheng Liu-Fang, Wu Kai, Yu Xiao-Hong and Yeo E.T. Anthony, Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (2) . https://dx.doi.org/10.2174/18715206113136660373
DOI https://dx.doi.org/10.2174/18715206113136660373 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Intrathecal Administration of Melatonin Ameliorates the Neuroinflammation- Mediated Sensory and Motor Dysfunction in A Rat Model of Compression Spinal Cord Injury
Current Molecular Pharmacology Partners in Crime: NGF and BDNF in Visceral Dysfunction
Current Neuropharmacology The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers
Protein & Peptide Letters Ceramic Nanoparticles: Fabrication Methods and Applications in Drug Delivery
Current Pharmaceutical Design Inhibition of Human 5-Lipoxygenase and Anti-Neoplastic Effects by 2-Amino-1,4-Benzoquinones
Medicinal Chemistry RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Chondroitin Sulfate and Sulfur Containing Chondroprotective Agents: Is there a Basis for their Pharmacological Action?
Current Rheumatology Reviews Organic Nanotheranostics for Photoacoustic Imaging-Guided Phototherapy
Current Medicinal Chemistry miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles
Current Medicinal Chemistry Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Managing Skin Malignancies- How Family Doctors, Plastic Surgeons, and Dermatologists Can Help
Current Cancer Therapy Reviews Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Current Vascular Pharmacology Role of Carbon Monoxide in Kidney Function: Is a little Carbon Monoxide Good for the Kidney?
Current Pharmaceutical Biotechnology Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology Recent Progress on Anti-Liver Fibrosis Candidates in Patents of Herbal Medicinal Products
Recent Patents on Food, Nutrition & Agriculture